Published in Blood Weekly, October 14th, 2004
The research will be funded through its new JDRF - Industry Discovery and Development Partnership Program that will assist ESI's development of newly derived nonxenograft human embryonic stem (hES) cells, for ultimate use in the production of hES cell-derived islets for the treatment of diabetes.
As a result of past research funded by the JDRF, it has been determined that the transplantation of insulin-producing islet cells currently offers the best hope for a cure for people with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.